The findings from this systematic review suggest a role for statin drugs in patients with COPD and coexisting CVD, evidence of increased systemic inflammation, or hyperlipidemia with respect to improving exercise tolerance and pulmonary function.
All all-cause, COPD and cardiovascular disease mortality was analyzed among men and women in relation to AL<sub>GOLD</sub> and AL<sub>LLN</sub>, adjusted for age and smoking.
A total of 52 patients with OSA requiring CPAP > 15 cm H<sub>2</sub> O (71% male, age: 58 (15) years, BMI: 42.6 (10.1) kg/m<sup>2</sup> , apnoea-hypopnoea index (AHI): 51.1 (30.4)/h) were studied; 62% had respiratory co-morbidities affecting nocturnal breathing including obesity hypoventilation syndrome and COPD; 25% had neuromuscular conditions; and 17% had cardiovascular disease.
We performed a secondary cohort analysis of the SUMMIT (Study to Understand Mortality and Morbidity) trial, a convenience sample of current/former smokers with moderate COPD from 1,368 centers in 43 countries.All had CVD or increased CVD risk.